先天性孤立型高胰岛素血症
Congenital isolated hyperinsulinism
定义 英文原文(暂无中文)
A rare endocrine disease characterized by an excessive or uncontrolled insulin secretion and recurrent episodes of hypoglycemia that can result in neurological sequelae if left untreated. There are two forms according to the response to first line treatment: diazoxide-sensitive and diazoxide-resistant hyperinsulinism; and three histopathological forms: focal, diffuse and atypical forms. Focal forms are only observed in early-onset cases of diazoxide unresponsive patients.
别名
婴儿持续高胰岛素血性低血糖
基本事实
- 遗传方式
- 常染色体显性、常染色体隐性
- 发病年龄
- 儿童期、婴儿期、新生儿期
- 患病率
- 1-9 / 100 000(Czech Republic)
相关基因 8来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来,「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| ABCC8 | ATP binding cassette subfamily C member 8 | ORPHA:276575 |
| GCK | glucokinase | ORPHA:79299 |
| GLUD1 | glutamate dehydrogenase 1 | ORPHA:35878 |
| HNF1A | HNF1 homeobox A | ORPHA:324575 |
| HNF4A | hepatocyte nuclear factor 4 alpha | ORPHA:263455 |
| KCNJ11 | potassium inwardly rectifying channel subfamily J member 11 | ORPHA:276580 |
| SLC16A1 | solute carrier family 16 member 1 | ORPHA:165991 |
| UCP2 | uncoupling protein 2 | ORPHA:276556 |
近两年的全球研究 16L2
2024/08 起在 Europe PMC 检索所得,按发表时间倒序显示最近 16 篇。本病的检索词较宽泛,命中数可能偏高,请以标题为准。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-07Two threats in early life: congenital hyperinsulinemic hypoglycemia and thrombosis
- 2026-06Near-Total Pancreatectomy for Congenital Hyperinsulinemic Hypoglycemia: A Single-Center Experience From a Low-Resource Setting in Sudan
- 2026-04A 13-Year-Old Girl with Congenital Hyperinsulinemic Hypoglycemia Due to an <i>ABCC8</i> Mutation and Recent Onset of Diabetes Mellitus: A Case Report and Literature Review
- 2026-04开放获取Anesthesia considerations in pediatric pancreatectomy for congenital hyperinsulinemic hypoglycemia: A retrospective case series
- 2026-02综述开放获取Genetic background of infantile hypophosphatemia: a narrative review
- 2026-01病例报告开放获取Congenital Hyperinsulinemic Hypoglycemia With a New HADH Mutation and Pancreatic Overexpression of GLP-1 Receptors
- 2025-11综述开放获取Expert consensus on the off-label use of drugs for pediatric rare diseases in China (2025 edition)
- 2025-08病例报告开放获取Biparental and Androgenetic Somatic Mosaicism with Presentation of Non-Syndromic Severe Neonatal Hyperinsulinemia
- 2025-07开放获取Trisomy 13 as a risk factor for pulmonary hypertension induced by diazoxide
- 2025-06开放获取Performance of ChatGPT-4o and Four Open-Source Large Language Models in Generating Diagnoses Based on China's Rare Disease Catalog: Comparative Study
- 2025-06病例报告开放获取Multi-locus methylation analyses reveal GNAS methylation defects in three patients with the Beckwith-Wiedemann syndrome phenotype and no molecular defects in the 11p15.5 imprinted region
- 2025-04病例报告开放获取A KDM6 A variant in a Chinese female patient with diabetes mellitus and oligomenorrhea: a case report
- 2025-01病例报告开放获取Identification of a novel heterozygous GPD1 missense variant in a Chinese adult patient with recurrent HTG-AP consuming a high-fat diet and heavy smoking
- 2024-11综述开放获取Genetic Variations in Hyperinsulinemic Hypoglycemia: Active versus Inactive Mutations
- 2024-11开放获取A Comprehensive Target Panel Allows to Extend the Genetic Spectrum of Neuroendocrine Tumors
- 2024-09开放获取A Novel De Novo Gain-of-Function <i>CACNA1D</i> Variant in Neurodevelopmental Disease With Congenital Tremor, Seizures, and Hypotonia
境外已获批用于本病的药物 0L2
欧盟与美国均未检索到已获批用于本病的药物。
已获孤儿药资格、尚未获批的在研药物(2 项)
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励,不代表这个药已被证明有效,也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
数据来自欧洲药品管理局(EMA)的药品与孤儿药资格公开导出表,以及美国 FDA 孤儿药资格数据库。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
在中国开展的临床试验 3L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。
当前没有检索到登记为可入组的试验。
其他状态的试验(3 项)
- 状态未知NCT0256037668Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis中国研究中心 1 个:Beijing
- 状态未知NCT03930368Application of Raw Corn Starch on Patients With Insulinoma中国研究中心 1 个:Beijing
- 已完成NCT05171751Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia中国研究中心 1 个:Beijing
中国境外的在招试验 4L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
共 4 项。
- 招募中NCT0470691018F-DOPA II - PET Imaging Optimization加拿大
- 招募中NCT0420560418FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism美国
- 招募中NCT02021604Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma美国
- 可获取(拓展性用药)NCT0191614818F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia美国
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)